These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16177668)

  • 1. Pharmacological treatment of chronic heart failure according to the 2005 guidelines of the European Society of Cardiology.
    Voors AA; van Veldhuisen DJ
    Minerva Cardioangiol; 2005 Aug; 53(4):233-9. PubMed ID: 16177668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between cardiologists and internists in the management of heart failure. Medical guidelines compared with every-day practice.
    Stawicki S; Roik M; Jasik M; Kosior D; Scisło P; Kochanowski J; Dembe K; Steckiewicz R; Karnafel W; Opolski G
    Kardiol Pol; 2004 Nov; 61(11):431-9; discussion 440-1. PubMed ID: 15883591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current guidelines in the pharmacological management of chronic heart failure.
    Metra M; Nodari S; Dei Cas L
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S11-6. PubMed ID: 15526236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure.
    Howard PA; Cheng JW; Crouch MA; Colucci VJ; Kalus JS; Spinler SA; Munger M
    Ann Pharmacother; 2006 Sep; 40(9):1607-17. PubMed ID: 16896019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Triple/quadruple therapy in heart failure: integrating scientific evidence with clinical reasoning].
    Sinagra G; Sabbadini G; Zecchin M; Di Lenarda A
    G Ital Cardiol (Rome); 2007 Sep; 8(9):559-67. PubMed ID: 17972425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of congestive heart failure].
    Aarønaes M; Atar D; Bonarjee V; Gundersen T; Løchen ML; Mo R; Myhre ES; Omland T; Rønnevik PK; Vegsundvåg J; Westheim A
    Tidsskr Nor Laegeforen; 2007 Jan; 127(2):174-7. PubMed ID: 17237864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
    Jotkowitz AB; Porath A; Shotan A; Mittelman M; Grossman E; Zimlichman R; Lewis BS; Caspi A; Gottlieb S; Garty M;
    Isr Med Assoc J; 2006 Dec; 8(12):875-9. PubMed ID: 17214110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure?
    Turley AJ; Raja SG; Salhiyyah K; Nagarajan K
    Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1141-6. PubMed ID: 18541605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacotherapy of chronic heart failure in clinical practice].
    Halawa B
    Pol Merkur Lekarski; 2004 Apr; 16(94):307-12. PubMed ID: 15517921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians.
    Remme WJ; McMurray JJ; Hobbs FD; Cohen-Solal A; Lopez-Sendon J; Boccanelli A; Zannad F; Rauch B; Keukelaar K; Macarie C; Ruzyllo W; Cline C;
    Eur Heart J; 2008 Jul; 29(14):1739-52. PubMed ID: 18506054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of ARB in heart failure].
    Tsutsui H
    Nihon Rinsho; 2009 Apr; 67(4):751-7. PubMed ID: 19348238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S
    Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.
    Ahmed A
    J Am Geriatr Soc; 2003 Jan; 51(1):123-6. PubMed ID: 12534856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.